CD8A and neoplasm: Taken together, these results indicate STAT3 inhibits the ability of the CD103+ cDC1 vaccine to induce tumor-antigen specific CD8+ T cell- and Th1 cell-mediated immunity in the murine breast TME and TdLNs.